Search the Newsreel

Earnings call transcript: Biofrontera tops Q2 2026 estimates, shares jump 9.6%

Biofrontera reported strong Q2 2026 results with a 33% increase in net product revenue to $12 million and gross margin of 80%, achieving near breakeven adjusted EBITDA. The company highlighted ongoing commercial momentum, including an 18.6% increase in first-half order count, and provided updates …

Form 8K Biofrontera Inc For: 13 August By Investing.com

This article reports that Biofrontera Inc. filed a Form 8K on August 13. The filing is a standard disclosure document used by companies to announce significant events that investors should know about. No specific details about the content of the 8K filing are provided …

Price to earnings forward of Biofrontera Inc. – BOATS:BFRIW

The article discusses the "Price to earnings forward" metric for Biofrontera Inc. (BFRIW), listed on the Blue Ocean Alternative Trade System (BOATS). It appears to be a stub or a data point from a financial platform, indicating market closed status and no trades, with …

Biofrontera Inc. (BFRI) Reports Q2 Loss, Beats Revenue Estimates

Biofrontera Inc. (BFRI) reported a Q2 loss of $0.05 per share, exceeding the Zacks Consensus Estimate of a $0.17 loss, and posted revenues of $12 million, surpassing estimates by 33.37%. Despite a mixed trend in estimate revisions leading up to the report, the company …

BIOFRONTERA ($BFRI) Releases Q2 2026 Earnings

Biofrontera Inc (BFRI) reported strong Q2 2026 results, driven by significant Ameluz growth and successful commercial expansion, leading to increased revenue and improved gross margins. Despite heightened operating expenses and competition, the company maintains a solid cash position and projects 30-35% revenue growth for …

Biofrontera (BFRI) investor Rosalind discloses 9.9% stake and 9.99% blocker

Rosalind Advisors, Inc., Rosalind Master Fund L.P., Steven Salamon, and Gilad Aharon have disclosed an amended 9.9% stake in Biofrontera Inc. (BFRI) through a Schedule 13G/A filing. The group beneficially owns 1,275,609 common shares, representing approximately 9.96% of the outstanding common shares. While they …

MicroPort CardioFlow Signals Revenue Surge as CRM Acquisition Fuels Global Growth

Biofrontera Inc. (BFRI) Stock Price, News, Quote & History

This article provides comprehensive financial information for Biofrontera Inc. (BFRI), a biopharmaceutical company specializing in dermatological treatments. It includes current stock price, historical data, performance metrics against the S&P 500, earnings trends, analyst insights, and key valuation measures. The company commercializes products like Ameluz …

Biofrontera Inc (BFRI) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Biofrontera Inc (BFRI), detailing its current earnings forecast score, average price target from analysts, and expected revenue and EPS for upcoming quarters. Two analysts rate BFRI as a "Buy" with a price target of $6.00, suggesting a …

BFRI Q2'26 Earnings: EPS estimate is (0.10) USD

Biofrontera Inc. (BFRI) is scheduled to release its Q2'26 earnings on August 7th. Analysts estimate the company will report revenue of $9.50 million and an earnings per share (EPS) of ($0.10) for the quarter. The article also provides historical reported and estimated revenue and …

Biofrontera schedules Aug. 13 webcast for business update

Biofrontera Inc. (NASDAQ: BFRI) announced it will report its second-quarter 2026 financial results on Thursday, August 13, 2026, before market open. Management will host a conference call and webcast at 10:00 a.m. Eastern Time on the same day to discuss the results and provide …

Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026

Biofrontera Inc. (NASDAQ: BFRI), a U.S. specialty dermatology company, announced it will report its second-quarter 2026 financial results on Thursday, August 13, 2026, before the market opens. Following the release, management will host a conference call and webcast at 10:00 a.m. Eastern Time to …

MicroPort CardioFlow signs two major Shanghai production leases

Biofrontera Inc (BFRI) Financial Health: Profitability & Balance Sheet Analysis

The article provides an analysis of Biofrontera Inc's financial health, indicating a stable financial status and high operating efficiency with a current financial score of 8.06. It highlights the company's latest quarterly revenue of $10.08 million, showing a 17.42% year-over-year increase, and a 13.06% …

Form 4 Biofrontera Inc For: 29 July By Investing.com

This article reports on a Form 4 filing for Biofrontera Inc. related to July 29th. It is a brief announcement without further details, typical of financial news sites reporting on regulatory filings. The article also includes various market data and other news headlines from …

Biofrontera Inc (BFRI) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Biofrontera Inc (BFRI), stating its current valuation score is 9.06 and ranks 55 out of 155 in the Pharmaceuticals industry. It highlights the company's P/E ratio of -1.21 but notes that relevant data for P/B, P/S, and …

Biofrontera Inc. Revenue Breakdown – NASDAQ:BFRI

Biofrontera Inc. (NASDAQ: BFRI) generated $41.70 million in revenue last year, primarily from its Pharmaceutical Products segment. This revenue marks an increase from $37.32 million in the previous year. The United States was the company's sole significant regional contributor, accounting for all reported revenue.

BFRI|Biofrontera Inc|Price:1.050|Chg%:-0.040

This article provides a detailed financial overview of Biofrontera Inc (BFRI), including its latest earnings report from May 14, 2026, with an EPS forecast of -0.12 and revenue forecast of 10.25M. It presents comprehensive quarterly and annual financial statements such as income statements, balance …

Biofrontera Inc (BFRI) Cash Flow

This article provides a detailed cash flow statement for Biofrontera Inc (BFRI), covering quarterly and annual data for operating, investing, and financing activities. It presents financial figures in millions of USD, along with year-over-year percentage changes, and includes FAQs explaining key cash flow concepts …

Biofrontera Inc (BFRI) Income Statement

This article presents the quarterly and annual income statements for Biofrontera Inc (BFRI), providing detailed financial figures such as total revenue, cost of revenue, operating expenses, and net income stretching back to Q1 2020. It allows users to analyze the company's financial performance and …

Biofrontera Inc (BFRI) Balance Sheet

This article presents the quarterly and annual balance sheets for Biofrontera Inc (BFRI), allowing users to evaluate the company's financial health, analyze fundamentals, and calculate key financial ratios. It includes detailed data on assets, liabilities, and shareholders' equity, covering various periods up to FY2026Q1. …

Biofrontera targets cash flow breakeven in 2026 while aiming for 80%-85% gross margin

Biofrontera AG announced its goal to achieve cash flow breakeven by 2026, targeting an 80%-85% gross margin. The company plans to expand its sales force in the first half of 2025 and is exploring a potential listing on Nasdaq to enhance capital market access …

WINNERS & LOSERS: Angus Energy revenue up; Iofina production jumps

Price to earnings forward of Biofrontera Inc. – NASDAQ:BFRI

Biofrontera Inc.'s (NASDAQ:BFRI) Path To Profitability

Biofrontera (BFRI) Q1 2026 Earnings Transcript

BIOFRONTERA ($BFRI) Releases Q1 2026 Earnings

Biofrontera Inc. (BFRI) Reports Q1 Loss, Beats Revenue Estimates

EARNINGS AND TRADING: Iofina celebrates "record" annual results

Iofina targets 5% of world iodine output as record results underpin expansion push - UPDATE

Brigit Biofarmaka (OBAT) Gelar RUPST 11 Mei, Bahas Kinerja hingga Penggunaan Laba

Iofina shares jump 12% as record Q1 output drives guidance upgrade

Market Still Lacking Some Conviction On Biofil Chemicals and Pharmaceuticals Limited (NSE:BIOFILCHEM)